21 Jun2022

SQZ Biotechnologies Presents Celiac Disease Tolerizing Antigen Carrier Preclinical Data at 2022 Federation of Clinical Immunology Societies (FOCIS) Annual Meeting

Written by 2020HCP.com. Posted in News

WATERTOWN, Mass.–(BUSINESS WIRE)– SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today presented Tolerizing Antigen Carrier (TACs) nonclinical results at the 2022 Federation of Clinical Immunology Sciences (FOCIS) annual meeting. The new celiac disease research found that in an in vitro assay, SQZ® TACs with deamidated gliadin, a protein associated with celiac disease, resulted in dendritic cell presentation of tolerizing antigens to T cells. In addition, the early data showed that the company’s Cell Squeeze® process could produce TACs with consistently high levels of antigen. The findings build upon additional research showing SQZ® TACs engineered to induce protection against type 1 diabetes could combat active autoimmune responses and prevent hyperglycemia.

28 Apr2022

SQZ Biotechnologies Receives FDA Fast Track Designation for its Lead Cell Therapy Candidate for the Treatment of HPV16+ Tumors

Written by 2020HCP.com. Posted in News

WATERTOWN, Mass.–(BUSINESS WIRE)– SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for the company’s lead cell therapy candidate, SQZ-PBMC-HPV, for the treatment of HPV16+ advanced or metastatic solid tumors.

11 Apr2022

SQZ Biotechnologies Presents New eAPC Preclinical Data Demonstrating That Multiplexed mRNA Engineering of Immune Cells Increases Killer T Cell Activity In Vivo

Written by 2020HCP.com. Posted in News

WATERTOWN, Mass.–(BUSINESS WIRE)– SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today shared enhanced antigen presenting cell (eAPC) preclinical data demonstrating that delivery of multiple mRNAs encoding for disease-specific antigens together with immune stimulators (CD86 costimulatory factor and membrane bound IL-2 and IL-12 cytokines) had a synergistic effect that substantially increased killer T cells in humanized mouse models.

05 Apr2022

SQZ Biotechnologies Publishes Comprehensive Preclinical Research on SQZ® TAC Platform’s Ability to Induce Multiple Key Mechanisms of Antigen-Specific Tolerance and Protect Against Type 1 Diabetes

Written by 2020HCP.com. Posted in News

WATERTOWN, Mass.–(BUSINESS WIRE)– SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced the publication of comprehensive preclinical research on the SQZ® Tolerizing Antigen Carrier (TAC) platform. The data, published in Frontiers in Immunology, demonstrated that TACs can induce multiple key mechanisms of antigen-specific tolerance in various model systems, including deletion of autoreactive T cells, anergy, and expansion of regulatory T cells (Tregs) capable of bystander suppression. In an in vivo model of type 1 diabetes (T1D), the TAC treatment was able to combat active autoimmune responses and prevent hyperglycemia.

23 Feb2022

Verizon, Bloomberg Media, Zixi & AWS test how 5G & edge compute can transform broadcast

Written by 2020HCP.com. Posted in News

NEW YORK – Verizon, Bloomberg Media, Zixi and Amazon Web Services (AWS) are working together to test how 5G and mobile edge computing can transform how global business news is produced, delivered and consumed. Using Verizon 5G Edge with AWS Wavelength, Bloomberg Media will be able to package and deliver live 4K Ultra High Definition (UHD) content without the need for satellites, allowing for fast and efficient content delivery.

Latest News